Mercy Medical Center held a special blessing, dedication and recommitment ceremony Sept. 24 for the hospital’s latest technological advance, the Varian TrueBeam version 3.0 radiotherapy system in the ...

NEW YORK, Oct. 21, 2024 /PRNewswire/ -- Report with the AI impact on market trends - The Global Radiosurgery and Radiotherapy Robotics Market size is estimated to grow by USD 713.4 million from ...

DENVER, Sept. 8, 2022 /PRNewswire/ -- ViewRay, Inc. (MRXC) (Nasdaq: VRAY) announced today that GenesisCare, the largest global provider of cancer services across the USA, UK, Spain and Australia, has ...

CLEVELAND, Oct. 29, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced a collaboration with GenesisCare, the largest provider of cancer services in the UK, Spain and Australia, to ...

Artificial intelligence tools in neuro-oncology demonstrate robust performance in detecting brain metastases and predicting clinical outcomes.

Klarity now offers Klarity Prints™ Powered by 3D Systems, and adds VSP ® Bolus to its comprehensive range of radiotherapy solutions Klarity Prints is easy solution for radiotherapy clinics in United ...

DUBLIN, Calif. & JENA, Germany--(BUSINESS WIRE)--"While our focus has been on intraoperative radiotherapy for breast cancer, we now also offer patented radiation technology for patients with skin or ...

FORT MYERS, Fla.--(BUSINESS WIRE)--GenesisCare, one of the leading integrated cancer care providers in the United States, Australia, Spain, and the United Kingdom, will launch ViewRay’s advanced ...

Varian’s Halcyon and Ethos radiotherapy systems received two regulatory nods in short succession, with both U.S. FDA 510(k) clearance and CE marking. In addition, the company reported that the first ...

(MENAFN- GlobeNewsWire - Nasdaq) The global Robotic Radiotherapy Market is experiencing strong growth as rising cancer incidence and precision-focused treatment systems transform oncology care.

In LMICs, improved treatment compliance and access to radiotherapy achieved through the adoption of hypofractionated radiotherapy regimens has the potential to narrow the disparate oncologic outcomes ...